Bristol Myers Squibb's Applications for Deucravacitinib for the Treatment of Moderate to Severe Plaque Psoriasis Accepted by U.S. Food and Drug Administration and Validated by European Medicines Agency Pharmaceutical Investing
European Commission Approves KEYTRUDA® Plus LENVIMA® for Patients With Certain Types of Endometrial Carcinoma Pharmaceutical Investing
European Commission Approves KEYTRUDA® Plus LENVIMA® as First-Line Treatment for Adult Patients With Advanced Renal Cell Carcinoma Pharmaceutical Investing
Numinus Develops Proprietary Psychedelic Tests with New Toxicity and Potency Scans Pharmaceutical Investing
Thermo Fisher Scientific Confirms Detection of SARS-CoV-2 in Samples Containing the Omicron Variant with its TaqPath COVID-19 Tests Medical Device Investing
INVESTOR ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action Lawsuits filed on behalf of BMY, CTXS, OWLT, PTON Investors, Lead Plaintiff Deadlines Set Pharmaceutical Investing
Numinus Receives Conditional Approval to Graduate to the Toronto Stock Exchange Pharmaceutical Investing
Merck and Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Molnupiravir, an Investigational Oral Antiviral Medicine, in At Risk Adults With Mild-to-Moderate COVID-19 Pharmaceutical Investing
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS BMY, LSPD INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits Pharmaceutical Investing
Marvel Biosciences Reports MB-204 as Highly Effective at Treating Autism Behaviours in Shank3 Mouse Model
